Homepage / Technology / A scientific breakthrough offers hope for an AIDS vaccine
Dow stock Boeing is up over 100% in one year, and some say the run isn't over Google CEO: You don't need to code to be successful at many jobs of the future—but you'll need this Netflix could see a huge move on earnings next week Netflix shares to surge on big international subscriber gains, analyst predicts What will Trump say at Davos? Six analysts give their predictions I tried to get my iPhone 6 battery replaced — here's what happened Jan Koum got the idea for $19 billion WhatsApp after missing too many iPhone calls at the gym Home security firm ADT drops 10% in NYSE debut Cramer: I'm fine with Amazon raising monthly Prime prices because it's still cheap Staten Island-based 'CabbageTech' charged with bitcoin-related fraud after promising 300% returns in a week Kohl's shares could pop 50% as Amazon partnership ramps up Trump's market cheerleading tweets could end up fueling a bubble New GOP tax law will boost corporate earnings at least 10%, says Merrill Lynch wealth manager Rising mortgage rates could mean even fewer homes for sale this spring Nike shares jump after analyst predicts a rally on new sneaker sales Investor 'fear of missing out' runs wild as record amount of money flows into stocks the last four weeks A crucial German vote this Sunday is seen as the key near-term driver for euro/dollar Oil price rally will not persuade OPEC to end production cuts, analyst says LA Times' Levinsohn under investigation after report on sex harassment Amazon is raising its monthly Prime membership rate There's a new venture fund founded by a former DJI and Tesla engineer and an ex-Kleiner partner Amazon and Nvidia are hiring people to cozy up to health VCs The executive in charge of Facebook’s efforts to court China has left the company 6 global trends that can derail your portfolio in 2018 Huawei executives are self-imposing a fine of nearly half a million dollars for inflated sales data Square shares pop after analyst says its similar to 'Amazon or Google in their early days' London's 'almost toxic' housing market might not give investors the returns they are looking for Hot tech stock Nvidia has even more room to run, says technical analyst Gaming giant Nvidia, after 113% gain, could surge another 23%, BofA analyst says Walmart will see a larger breakout after ‘lost’ years, Oppenheimer analyst says The bull case for Netflix ahead of earnings The UK’s foreign minister wants to build a 22-mile bridge to France Rising hedge fund stars are crushing the market, taking crown away from Einhorn, Ackman New Zealand PM set to be only the second world leader to give birth while in office The bond yield that helps price all sorts of loans just jumped to its highest level since 2014 Berlusconi has been in politics for nearly three decades. This is the secret to his popularity Indonesian leader's third cabinet reshuffle could have elections implications Who are ‘Davos Man’ and ‘Davos Woman’? European stocks seen mixed ahead of earnings, data Bitcoin could be here for 100 years but it's more likely to 'totally collapse,' Nobel laureate says China says sunken Iranian tanker may be leaking bunker fuel South Korean group files complaint against Apple CEO over iPhone slowdown What happens during a US government shutdown Bitcoin is 'something regulators need to deal with but not ban,' says former FDIC chair Cramer Remix: How I decide which retailers are not buyable Cramer's lightning round: Hormel's one of the few food stocks I like Cramer tracks 4 growing market discrepancies: Rates, Trump, cryptocurrencies and stocks Asian markets poised to open with moderate gains despite softer US lead IBM executive says blockchain 'creates a lot of value' for manufacturers, retailers Bitcoin's on a wild ride, but investors have shown it's here to stay, analyst says Cramer: I've never seen a market like this in my life Atlassian beats estimates, but its shares fall anyway Snap laid off two dozen employees and half of them were from its content team Tesla bringing Model 3 to three East Coast showrooms This start-up founder has a novel strategy for getting ahead: Telling the truth Texas Instruments' long-time CEO is stepping down after the stock rallied 57% in the past year Trump says he called and thanked Tim Cook after Apple revealed its US investment plan There's 'no evidence' Tasers reduce police use of firearms, new study shows IBM shares fall despite first growth in 23 quarters Tim Cook tells Cramer: New tax law helped pave the way for Apple’s massive investment plan Uber's Kalanick ignored warnings from execs about buying self-driving truck start-up Otto, says report Washington, DC, and Austin are shaping up as strong contenders for Amazon's new headquarters Legacy airlines are facing new competitors on transatlantic routes Here’s how cities are reacting to being finalists for Amazon HQ2 A high schooler interviewed Apple CEO Tim Cook — and he told her his secret to success Another top Silicon Valley investor slams politically correct tech culture, praises China Steve Wozniak is still on Apple's payroll four decades after co-founding the company Bank of America loses its second head of tech and media banking in less than a year Three of the finalists for Amazon's second headquarters are in or near Washington DC Wrong on GE, market-beating value investor Bill Nygren says he is sticking by tanking blue chip Apple may have just saved the GOP Bitcoin rallies more than 30% to briefly top $12,000 in latest wild swing GE shares drop to 6-year low below $17 With eye on Brexit talks, May offers France money for border security Uber ex-CEO Travis Kalanick will officially be a billionaire Thursday, as deal with SoftBank closes The French government experiments with venture capitalism The World Bank’s “ease of doing business” report faces tricky questions Our Big Mac index shows fundamentals now matter more in currency markets The threat of tough regulation in Asia sends crypto-currencies into a tailspin Innovative materials from bamboo are helping a new industry to sprout A weak market for football rights suggests a lower value for sport Why driverless cars may mean jams tomorrow Chinese tech companies plan to steal American cloud firms’ thunder Masayoshi Son may raise yet more cash to pump into tech The hedge-fund delusion that grips pension-fund managers Ignore the bad housing starts number. Builder optimism and buyer demand are high Facebook launches 30-city Community Boost program Blockchain cryptocurrency wallet launches bitcoin buy and sell in the US to challenge Coinbase An overlooked, gutsy way for investors to make huge returns Tom Lee, bitcoin's earliest and most bullish forecaster on Wall Street, is even more positive after crash Netflix's original content will allow it to raise prices more than expected, Morgan Stanley says One way China could be clearing a path to investment ties in Western Europe It's a buy-the-dip story in the oil markets, says RBC's Helima Croft Intel's security patches are causing computers to randomly restart Comcast shares fall after downgrade on slowing broadband growth fear, streaming competition Forget DACA for now, let's keep the government open first, says GOP's Hensarling Tech giants are calling on Trump to preserve an immigration policy for spouses of skilled workers US housing starts down sharply on drop in single-family units Trump administration's infrastructure plan takes shape, focusing on state, local, and private financing Beware the ‘black hole’ that is GE, market watcher warns


A scientific breakthrough offers hope for an AIDS vaccine

Scientists are inching toward developing a vaccine for AIDS, an immunodeficiency disease caused by the HIV virus that currently affects 36.7 million people worldwide, according to the World Health Organization.

In a paper published in the journal Science in September, scientists from the National Institutes of Health and Paris-based pharmaceutical company Sanofi described a “three-pronged” antibody, engineered in a lab, that binds to three critical sites on the HIV virus. By attacking the virus from three sides, the “trispecific” antibody creates a roadblock that even HIV — known for its constant mutating — should struggle to circumvent.

“This is very impressive and really very exciting for people who are looking for ways to prevent HIV acquisition,” said Rowena Johnston, director of research at amfAR, a foundation that raises money for the study of AIDS.

Though therapies for HIV/AIDS now allow people to more effectively manage the disease, it still claims 1 million lives around the world every year and represents about $3.5 billion in annual U.S. health-care costs. The rate of new infections in the U.S. has fallen in recent years, to 37,600 in 2014 (the most recent year for which stats are available). But in Africa — where two-thirds of all new infections occur — there were 960,000 new AIDS/HIV cases in 2016.

Further alarming health advocates is the Trump administration’s decision to slash its global HIV/AIDS spending by 24 percent, leaving nonprofits like the Bill & Melinda Gates Foundation scrambling to make up the shortfall. “There’s no way to balance a cut in a rich country’s generosity,” said Mr. Gates in September.

The promise of an AIDS vaccine has tempted, but eluded, scientists for decades. It’s been 37 years since Margaret Heckler, Secretary of Health and Human Services under President Ronald Reagan, infamously told reporters at the press conference announcing the discovery of AIDS that a vaccine would be ready for testing within two years. Twenty-one years after that, the New England Journal of Medicine — following the collapse of yet another promising phase-3 study — referred to the flagging search for an AIDS vaccine as “a Sisyphean onslaught of disappointments.”

HIV is spread through the sharing of specific bodily fluids — blood, semen, breast milk and vaginal or rectal fluids — which typically occur during intercourse or the sharing of intravenous needles. Once inside the body, HIV attacks a certain kind of immune-system cell known as CD4. By destroying these cells, the virus makes it harder for your body to fight off disease, increasing the risk of major illness from even minor infections.

But in recent years, scientists have discovered a kind of antibody in people living longer with the virus, which has reinvigorated the pursuit. Known as broadly neutralizing antibodies, these Y-shaped proteins — which occur in about 20 percent of infected people living with HIV for two or more years — helps defend against multiple strains of HIV and are thought to play a role in helping people fend off the infection. Multiple studies have since tested ways in which broadly neutralizing antibodies could help stave off HIV infection or slow its growth in those already infected.

More from Modern Medicine:
Growing old with HIV after decades of drug success
A party drug could become next blockbuster antidepression treatment
New cure under way for the 80 million people in US dealing with hair loss

Of course, the antibodies have their limitations. “Each individual antibody only binds to one very specific component of the HIV envelope, or the outer covering,” said Anthony S. Fauci, director of the National Institute of Allergy and Infectious Diseases, who helped oversee the new study. But HIV is constantly mutating, so no single antibody can hold off the virus for long. Eventually, the virus will happen upon a mutation that allows it to get around the protection provided by the single antibody.

What the NIH and Sanofi scientists did was combine three broadly neutralizing antibodies into a single compound. Johnston, who was not involved in the research, compared the approach with antiretroviral therapy, which has become the standard in HIV treatment by slowing the virus’ growth through a strategic combination of drugs. “If you’re only taking one type of drug, then your HIV would escape from that,” she said. “It’s possible two would work, but three really seals the deal.”

The redundancy of three different antibodies makes escape-by-mutation practically impossible. “HIV would have to come up with such an elaborate set of mutations to escape from all three of these antibodies simultaneously that it’s almost certainly not going to happen,” she said.

Combining three antibodies into a single compound — a remarkable feat of engineering, noted Johnston — not only provides greater protection against the virus but is optimized to move swiftly through the arduous FDA-approval process.

“It’s very complicated to get approval to do a trial in which you’re trying to combine more than one thing,” said Johnston. “If you’re trying to do drug A and drug B, the FDA would prefer you start out looking at just drug A and just drug B before they give you permission to put A and B together.”

The trispecific antibody circumvents that process — an ancillary benefit that Fauci referred to as a “bonus.” “We weren’t thinking about the FDA when we did this,” he said.

If it proves safe and effective in humans, the drug could be used both as a vaccine and a treatment for people already living with the disease. A phase 1 trial is now slated to begin in late 2018. If all goes well, it could potentially be on the market within the next three years.

Still, Fauci was careful not to overstate the significance of the current findings.

“This is a solid incremental increase in our capability of dealing with and preventing HIV infection,” he said. “It’s significant, but it isn’t completely transforming.”

That could change, of course. But only time will tell. “It ain’t a breakthrough till it works,” Fauci said.

By Douglas Quenqua, special to CNBC.com

Source: Tech CNBC
A scientific breakthrough offers hope for an AIDS vaccine

Comments are closed.